Danaher (NYSE:DHR) is focusing on commercial execution, innovation and acquisitions as it seeks faster core growth and market ...
The company is seeing a big uptick in equipment orders. Danaher said it expects its acquisition of Masimo to be accretive to earnings this year. The life sciences industry has slowed since its ...
Danaher (NYSE:DHR) is highlighted as a major contributor to global adoption of single use bioreactors in bioprocessing ...
Jefferies Global Healthcare Conference 2026 November 17, 2026 5:00 AM ESTCompany ParticipantsJulie Montgomery - President, ...
Diversified science and technology company Danaher (NYSE:DHR) in Q4 CY2025, with sales up 4.6% year on year to $6.84 billion. Its non-GAAP profit of $2.23 per share was 1.8% above analysts’ consensus ...
Danaher stock gets a new regulatory catalyst as Cepheid secures IVDR CE marking for its Xpert Respiratory Panel. The test ...
The job cuts at Danaher’s molecular diagnostics subsidiary will take place by the end of the year and affect mostly ...
Danaher 's days in the portfolio may be numbered. We're again left disappointed after Danaher's latest acquisition plan failed to inspire Wall Street. Shares of the life sciences giant lost more than ...
Cytiva is expected to sustain high-single-digit long-term growth, supported by biologics, biosimilars and manufacturing ...
Danaher shares soared on Tuesday after the supplier of tools and equipment to drugmakers and hospitals provided an upbeat initial forecast for growth next year. After an extended stretch of ...
While the worst seem to be behind them, the business isn’t quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year ...